Sean Burroughs: 2025 Funding Rounds and Growing Therapeutic Trends
Sean Burroughs, President & Co-Founder at Thorough Group, shared a post on LinkedIn:
“I know there is a lot of bad news all over LinkedIn right now, so this Friday morning I am going to focus on some positives thus far in 2025!
Big Wins for Biotech: 2025 Funding Rounds & Growing Therapeutic Trends.
Despite the ups and downs of the market, biotech continues to push forward, with several companies securing major investment rounds early this year. Some of the biggest recent fundraises include:
- Abcuro, Inc – $200M (Autoimmune & Neuromuscular Diseases)
- Newleos Therapeutics – $93.5M (Next-Gen Oncology & Rare Diseases)
- Bambusa Therapeutics – $90M (RNA-Based Therapies)
- AdvanCell – $112M (Radiopharmaceuticals)
- Verdiva Bio – $410M (Obesity)
- Kardigan – $300M (Cardiovascular Disease)
- Aviceda Therapeutics – $207.5M (Ophthalmology)
- Tenvie Therapeutics – $200M – (Neurology)
- Timberlyne Therapeutics – $180M (Autoimmune Diseases)
- Tune Therapeutics – $175M (Chronic Disease)
- Ouro Medicines – $120M (Immunological Diseases)
- Umoja Biopharma – $100M (Oncology)
- Atalanta Therapeutics – $97M (Neurological conditions)
- Be Biopharma – $92M (Rare Diseases)
- A2 Biotherapeutics, Inc. – $80M (Oncology)
- Normunity – $75M (Oncology)
- XyloCor Therapeutics, Inc. – $67.5M (Cardiovascular Disease)
- Helicore Biopharma – $65M (Obesity)
- Light Horse Therapeutics – $62M (Oncology)
Public Offerings:
- Akero Therapeutics – $350M (Endocrinology and metabolic disorders)
- 89bio – $250M (Endocrinology and metabolic disorders)
- Disc Medicine – $225.5M (Hematology)
- Ascentage Pharma – $126.4M (Oncology)
Therapeutic Area Trends so far in 2025:
- Oncology & Immuno-Oncology – No surprise here, but we’re seeing growing investment in novel cancer therapies, especially in targeted radiopharmaceuticals and cell-based treatments.
- AI-Driven Drug Discovery – Companies like XtalPi ($267M) are fueling the AI revolution in biotech, making drug development faster and more precise.
- Neurological & Autoimmune Disorders – With the success of recent approvals, investors are increasingly backing companies tackling neurodegenerative diseases and autoimmune conditions.
- RNA & Genetic Medicines – The momentum from mRNA and gene-editing technologies isn’t slowing down, with startups securing big rounds to advance next-gen therapies.
For those of us in biotech hiring, this means a surge in demand for clinical, regulatory, and scientific talent—especially in these cutting-edge fields.
What do you think? Are these the therapeutic areas to watch in 2025, or do you see other big trends emerging?
Drop your thoughts in the comments!”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023